tiprankstipranks
Effector Therapeutics’ Stock Issuance Capped: Navigating the Lincoln Park Agreement’s Exchange Limit
PremiumCompany AnnouncementsEffector Therapeutics’ Stock Issuance Capped: Navigating the Lincoln Park Agreement’s Exchange Limit
24d ago
eFfector Therapeutics reports Q4 EPS ($3.42), consensus ($1.65)
PremiumThe Fly
eFfector Therapeutics reports Q4 EPS ($3.42), consensus ($1.65)
25d ago
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
PremiumPress Releases
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
25d ago
eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
PremiumPress ReleaseseFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
3M ago
eFFECTOR Therapeutics Secures $15M in Direct Offering
PremiumMarket News
eFFECTOR Therapeutics Secures $15M in Direct Offering
3M ago
eFfector to sell 1.49M shares at $10.075 in registered direct offering
PremiumThe Fly
eFfector to sell 1.49M shares at $10.075 in registered direct offering
3M ago
eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024
PremiumPress ReleaseseFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024
3M ago
eFfector Therapeutics board approves 1-for-25 reverse stock split
PremiumThe Fly
eFfector Therapeutics board approves 1-for-25 reverse stock split
3M ago
eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients
PremiumPress Releases
eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100